Open Peer Review on Qeios

Ibrutinib/Rituximab Regimen

National Cancer Institute

Source

National Cancer Institute. Ibrutinib/Rituximab Regimen. NCI Thesaurus. Code C160529.

A regimen consisting of ibrutinib and rituximab that may be used in the treatment of primary or previously treated Waldenström macroglobulinemia and certain non-Hodgkin lymphomas (NHL).